MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
Three Pivotal Drug Policy Organizations Hold Media Briefing/Q&A on DEA Rescheduling of Cannabis WASHINGTON, May 01, 2024 (GLOBE NEWSWIRE) -- What: The Multidisciplinary Association for Psychedelic Studies (MAPS), The Marijuana Policy Project (MPP), and the National Organization for the...
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders MAPS uses its over 30 years of experience in the psychedelic space to offer a first-of-its-kind gold-standard training program.
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Announces Celestial Plans for Its 38th Anniversary MAPS, which celebrates its 38th anniversary on April 8, will celebrate with a total solar eclipse at the Texas Eclipse 2024 festival in Texas
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference will convene in the...
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS